People · Operator
Named in public records as an officer, director or promoter · active 2019–2019 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MediSix Therapeutics, Inc. | — | Biotechnology | Series B | $42.9M | $647.6M | 2019 |
Sarah D. Lim at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sarah D. Lim on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Michael Carusi | 1 | 7 |
| Michael A. Carusi | 1 | 6 |
| George H. Poste | 1 | 2 |
| William A. Harrington | 1 | 1 |
| George A. Poste | 1 | 1 |
| Kenneth D. Noonan | 1 | 1 |
| Michael D. Carusi | 1 | 1 |
| Andrew R. Bruce | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.